Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

重症 COVID-19 患者对 SARS-CoV-2 感染的局部固有免疫力受损

阅读:3
作者:Carly G K Ziegler ,Vincent N Miao ,Anna H Owings ,Andrew W Navia ,Ying Tang ,Joshua D Bromley ,Peter Lotfy ,Meredith Sloan ,Hannah Laird ,Haley B Williams ,Micayla George ,Riley S Drake ,Taylor Christian ,Adam Parker ,Campbell B Sindel ,Molly W Burger ,Yilianys Pride ,Mohammad Hasan ,George E Abraham 3rd ,Michal Senitko ,Tanya O Robinson ,Alex K Shalek ,Sarah C Glover ,Bruce H Horwitz ,Jose Ordovas-Montanes

Abstract

SARS-CoV-2 infection can cause severe respiratory COVID-19. However, many individuals present with isolated upper respiratory symptoms, suggesting potential to constrain viral pathology to the nasopharynx. Which cells SARS-CoV-2 primarily targets and how infection influences the respiratory epithelium remains incompletely understood. We performed scRNA-seq on nasopharyngeal swabs from 58 healthy and COVID-19 participants. During COVID-19, we observe expansion of secretory, loss of ciliated, and epithelial cell repopulation via deuterosomal cell expansion. In mild and moderate COVID-19, epithelial cells express anti-viral/interferon-responsive genes, while cells in severe COVID-19 have muted anti-viral responses despite equivalent viral loads. SARS-CoV-2 RNA+ host-target cells are highly heterogenous, including developing ciliated, interferon-responsive ciliated, AZGP1high goblet, and KRT13+ "hillock"-like cells, and we identify genes associated with susceptibility, resistance, or infection response. Our study defines protective and detrimental responses to SARS-CoV-2, the direct viral targets of infection, and suggests that failed nasal epithelial anti-viral immunity may underlie and precede severe COVID-19.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。